Pharma BD Deal Intelligence
Total loss: entire deal value written off within a year, business unit shuttered by 2004
Full analysis, sources & comparables →Announcement: all-share merger (0.2 Sequenom share per Gemini share) intended to accelerate identification of disease-associated genes; CEO Tony Schuh: 'We…
Gemini Genomics' UK-based clinical-genetics business was acquired by Sequenom in a stock deal originally valued near $238M to expand drug-development and…
Nature Biotechnology ('Sequenom steps toward drug development') frames the Gemini Genomics merger as Sequenom moving up the value chain from genotyping toward…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Stock-for-stock announced 2001-05-29, closed 2001-09. Genotyping/SNP platform plus clinical genetics. Final value ~$238M at announce.
Total loss: entire deal value written off within a year, business unit shuttered by 2004
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sequenom Inc. / Gemini Genomics plc (UK) (this deal) | 2001 | $238M | 11 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals